Biocure Technology Inc. announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. whereby the Company will acquire all of the issued.
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including
EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut.
VANCOUVER, BC, Sept. 14, 2023 /CNW/ - The following issues have been halted by CIRO: Company: Biocure Technology Inc. CSE Symbol: CURE All Issues: Yes Reason: Pending News Halt Time (ET): 4:26 PM CIRO can make a